Boston Scientific's stock experienced a sharp intraday decline of 13.30% on Wednesday, following the release of its fourth-quarter 2025 financial results and forward-looking guidance that disappointed investors.

While the medical device maker reported strong fourth-quarter performance with adjusted earnings of $0.80 per share beating estimates of $0.78 and revenue of $5.29 billion slightly exceeding expectations, investor focus shifted to the company's cautious outlook. Boston Scientific issued first-quarter 2026 adjusted EPS guidance of $0.78 to $0.80, with the high end matching but not exceeding analyst expectations of $0.80. More concerning to investors was the full-year 2026 guidance, with adjusted EPS projected between $3.43 and $3.49, where the midpoint of $3.46 falls below the average analyst estimate of $3.47.

The company's projected organic revenue growth of 10% to 11% for 2026 represents a significant slowdown from the 15.8% organic growth achieved in 2025. Additionally, sales of key growth drivers disappointed, with the Electrophysiology franchise revenue of $890 million missing Street estimates of $933 million, and sales of the Watchman stroke prevention device coming in below consensus, particularly in the U.S. market. This combination of tempered growth expectations and underperformance in critical product segments triggered the substantial sell-off.